Clinical Trials

METASTATIC
CC#08451-B: Safety profile assessment of theraspheres used for treatment of metastatic liver disease from primary colorectal, NET, melanoma, & breast cancers refractory to chemo
Contact: Kimberly Morrell or Leslie Lind (415) 353-1300 kimberly.morrell@radiology.ucsf.edu or leslie.lind@radiology.ucsf.edu
 
CC# 12451: A phase III clinical trial evaluating TheraSphere® in patients with metastatic colorectal carcinoma to the liver who have failed first line chemotherapy (TS-102)
Contact: Regina LInetskaya (415)353-7145: LInetskayaR@cc.ucsf.edu
 
CC# 124522 (GSK# MEK116833): An Open-Label, Three-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E or V600K Positive Colorectal Cancer
Contact: Ryan McWhirter (415)353-7792: McWhirterR@cc.ucsf.edu
 
NEOADJUVANT RECTAL
Alliance N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Contact: Sharvina Ziyeh (415) 353-7683: ZiyehS@cc.ucsf.edu
 
ADJUVANT
CALGB 80702: Phase III Trial of 6 vs 12 Treatments of Adjuvant FOLFOX +Celecoxib/Placebo for Resected Stage III Colon Cancer
Contact: Sharvina Ziyeh (415) 353-7683: ZiyehS@cc.ucsf.edu

CC#11956: A Phase I Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Contact: Alex Peck (415) 353-9535: PeckAD@cc.ucsf.edu
 
CC#12955: Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of
AGS 22M6E Given as Monotherapy Followed by Expansion Cohorts in Subjects with Malignant
Solid Tumors that Express Nectin-4
Contact: Noah Strait (415) 514-6363: straitn@cc.ucsf.edu
 
CC#12951: A Phase 1/1b Dose-Escalation Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumor Malignancies and Assessment of MYC Oncogene Overexpression; Paclitaxel MUST be indicated for tumor type
Contact: Saloni Mathur (415) 514-6674: MathurS@cc.ucsf.edu
 
CC# 11955: Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination with PCI24871 in Patients with Metastatic Solid Tumors
Contact: Saloni Mathur (415) 514-6674: MathurS@cc.ucsf.edu
 
CC# 10993: A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability , Pharmakokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally ; Open to patients with HCC and NET (non-pancreatic or unknown origin)
Contact: Alex Peck (415) 353-9535: PeckAD@cc.ucsf.edu
 
CC# 109910: A Phase 1 Study of LY2875358 in Patients with Advanced Cancer; Open to patients with HCC, requires high c-met expression
Contact: Alex Peck (415) 353-9535: PeckAD@cc.ucsf.edu
 

 

CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Contact: Adrienne Brenner (415) 353-9544: BrennerA@cc.ucsf.edu
 
CC# 13451: An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Contact: Hilary Chan (415)514-5633 : ChanH@cc.ucsf.edu

CC# 13452: Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with ‘Traditional’ and ‘Non-Traditional’ HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
Contact: Cendy Carrasco (415) 885-7740: CarrascoC@cc.ucsf.edu

CC# 124511: Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Contact: Ryan McWhirter (415) 353-7792: McWhirterR@cc.ucsf.edu

CALGB 80802: Phase III Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Contact: Hilary Chan (415)514-5633 : ChanH@cc.ucsf.edu
 
CC# 11452: Randomized Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma who Have Had Disease Progression on Sorafenib or Are Not Eligible to Receive Sorafenib
Contact: Adrienne Brenner (415) 353-9544:BrennerA@cc.ucsf.edu
 
CC# 124517: A phase 1A/1B, multi-center, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the pleiotropic pathway modifier CC-122 administered orally to subjects with advanced solid tumors, non-hodgkin’s lymphoma or multiple myeloma (HCC patients may enroll)
Contact: Sharvina Ziyeh (415) 353-7683: ZiyehS@cc.ucsf.edu
 
CC# 124510: A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients with Advanced Solid Malignancies
Contact: Sharvina Ziyeh (415) 353-7683: ZiyehS@cc.ucsf.edu
 
CC# 12454: A Randomized Three Arm Phase II Study of (1) Everolimus, (2)Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC).
Contact: Regina Linetskaya (415)353-7145: LInetskayaR@cc.ucsf.edu
 
CC# 10993 : A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability , Pharmakokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally ; Open to patients with HCC and NET (non-pancreatic or unknown origin)
Contact: Roth Ea (415) 353-7710: EaR@cc.ucsf.edu
 
CC#109910:A Phase 1 Study of LY2875358 in Patients with Advanced Cancer; Open to patients with HCC, requires high c-met expression
Contact: Alex Peck (415) 353-9535: PeckAD@cc.ucsf.edu
 

CC#08451:A: Safety profile assessment of therasphere yttrium-90 glass microspheres used for treatment of HCC: A pilot study
Contact: Kimberly Morrell or Leslie Lind (415) 353-1300 kimberly.morrell@radiology.ucsf.edu or leslie.lind@radiology.ucsf.edu
 
 

 
CC# 10993 : A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability , Pharmakokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally ; Open to patients with HCC and NET (non-pancreatic or unknown origin)
Contact: Roth Ea (415) 353-7710: EaR@cc.ucsf.edu
 
CTSU-E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
Contact: Regina LInetskaya (415)353-7145: LInetskayaR@cc.ucsf.edu
 

CC# 114520: Phase II Study of Axitinib in Patients with Advanced Carcinoid Tumors (MCC #16438)
Contact: Adrienne Brenner (415) 353-9544: BrennerA@cc.ucsf.edu
 
Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND #75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
Contact: Regina LInetskaya (415)353-7145: LInetskayaR@cc.ucsf.edu
 
CC# 124521: A Phase 3, Randomized, Placebo-controlled, Parallelgroup, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy
Contact: Cendy Carrasco (415) 885-7740: CarrascoC@cc.ucsf.edu
 

 CC# 13455: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Contact: Hilary Chan (415)514-5633: ChanH@cc.ucsf.edu
 
CC# 13454:  A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel Combined With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial)
Contact: Hilary Chan (415)514-5633: ChanH@cc.ucsf.edu
 
CC# 13456: Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Contact: Jennifer Luan (415)514-6220: LuanJ@cc.ucsf.edu